Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-12-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details amounts, dates, expected yields, and risk control measures related to cash management of idle raised funds. The document references prior approvals by the board and shareholders and provides updates on the status of these cash management activities. It does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory announcement about the use of raised funds, specifically cash management progress, rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including the use of raised funds for cash management.
2024-12-13 Chinese
金陵药业股份有限公司关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the national drug regulatory authority. It details the drug's basic information, approval status, and potential impact on the company. There is no financial data, no mention of annual or quarterly reports, no audit information, no management changes, no voting results, or other report types. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2024-12-11 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details amounts, dates, expected yields, risk control measures, and the impact on company operations. The document is a specific update on the use of raised funds for cash management, not a full financial report or audit. It is not a report publication announcement since it contains substantive information about the cash management activities and progress. It is not an earnings release or interim report as it lacks comprehensive financial statements or analysis. The document fits best as a Capital/Financing Update (CAP) because it provides updates on the company's use of raised funds and cash management activities, which relate to capital management and financing activities.
2024-12-09 Chinese
金陵药业股份有限公司关于全资子公司清算注销完成的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of liquidation and deregistration of a wholly-owned subsidiary of the company. It references a prior board meeting decision and a regulatory notification confirming the completion of the subsidiary's deregistration. The document is short (559 characters) and serves as a formal public notice rather than a detailed financial report or analysis. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive information about the deregistration event itself. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-11-20 Chinese
金陵药业股份有限公司关于收购新工基金部分份额及新工基金非现金分配股权暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of acquiring part of the shares in a medical industry investment fund and related non-cash equity distribution and related party transactions. It details the approval of the transaction by the board and shareholders, the completion of registration procedures, and the updated fund partner composition. The document is a corporate announcement about a capital transaction involving fund shares and equity distribution, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather updates on a financing-related transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on transaction progress, not a report publication or regulatory filing. Confidence is high due to clear transaction details and fund share acquisition context.
2024-11-18 Chinese
2024-093金陵药业股份有限公司关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Jinling Pharmaceutical Co., Ltd. regarding the completion of repurchase and cancellation of certain restricted stocks under the 2021 restricted stock incentive plan. It details the number of shares repurchased, the reasons for repurchase, adjustments to repurchase prices, funding sources, verification by an accounting firm, and the impact on the company's share capital structure. The document is a formal disclosure about a share repurchase and cancellation event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on the transaction of the company's own shares. Therefore, it fits the category of "Transaction in Own Shares" (POS). The document length (6460 characters) and content confirm it is a full announcement, not a brief notice or a report publication announcement.
2024-11-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.